FI2931265T6 - Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa - Google Patents
Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa Download PDFInfo
- Publication number
- FI2931265T6 FI2931265T6 FIEP13862780.7T FI13862780T FI2931265T6 FI 2931265 T6 FI2931265 T6 FI 2931265T6 FI 13862780 T FI13862780 T FI 13862780T FI 2931265 T6 FI2931265 T6 FI 2931265T6
- Authority
- FI
- Finland
- Prior art keywords
- axl
- variant polypeptide
- inhibitor
- seq
- soluble axl
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 5
- 230000002001 anti-metastasis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims 2
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102220012991 rs111033344 Human genes 0.000 claims 2
- 102220044222 rs587781255 Human genes 0.000 claims 2
- 102220258833 rs764229797 Human genes 0.000 claims 2
- 102220098139 rs878852992 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102200053909 rs2638525 Human genes 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737276P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/074786 WO2014093690A1 (en) | 2012-12-14 | 2013-12-12 | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI2931265T6 true FI2931265T6 (fi) | 2023-05-23 |
Family
ID=50934967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP13862780.7T FI2931265T6 (fi) | 2012-12-14 | 2013-12-12 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9822347B2 (enExample) |
| EP (2) | EP3326622B1 (enExample) |
| JP (2) | JP6345690B2 (enExample) |
| AU (3) | AU2013359179B2 (enExample) |
| CA (1) | CA2894539C (enExample) |
| DK (2) | DK3326622T3 (enExample) |
| ES (2) | ES2862335T3 (enExample) |
| FI (1) | FI2931265T6 (enExample) |
| NO (1) | NO3049208T3 (enExample) |
| PT (2) | PT3326622T (enExample) |
| WO (1) | WO2014093690A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| WO2013090776A1 (en) | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
| KR20200085307A (ko) * | 2017-11-04 | 2020-07-14 | 아라바이브 바이올로직스, 인크. | Axl 유인 수용체를 이용한 전이성 암의 치료 방법 |
| JP2024533362A (ja) * | 2021-09-11 | 2024-09-12 | アラヴィヴ インコーポレイテッド | Ａｘｌデコイ受容体を一次治療として使用する局所進行又は転移性膵臓腺がんを治療する方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5538861A (en) | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US20030166107A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| AU2003304180A1 (en) | 2002-09-24 | 2005-01-04 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| US20070142273A1 (en) | 2003-04-18 | 2007-06-21 | Sherif Daouti | Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis |
| JP2005278631A (ja) | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
| CA2630475A1 (en) | 2004-11-24 | 2006-06-01 | The Regents Of The University Of Colorado | Mer diagnostic and therapeutic agents |
| US7932032B2 (en) | 2005-05-02 | 2011-04-26 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
| US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
| CN101679313A (zh) | 2007-04-13 | 2010-03-24 | 休普基因公司 | 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂 |
| CA2692320A1 (en) | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| CA2747678A1 (en) * | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| RU2556822C2 (ru) * | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2013090776A1 (en) * | 2011-12-15 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl/gas6 signaling in the treatment of disease |
| US20150315552A1 (en) | 2012-12-14 | 2015-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL Signaling in Primary Tumor Therapy |
| FI2931265T6 (fi) | 2012-12-14 | 2023-05-23 | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| US20160266136A1 (en) * | 2013-08-30 | 2016-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
| CA2909669C (en) * | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
| EP3233902B1 (en) * | 2014-12-18 | 2020-09-09 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
-
2013
- 2013-12-12 FI FIEP13862780.7T patent/FI2931265T6/fi active
- 2013-12-12 US US14/650,854 patent/US9822347B2/en active Active
- 2013-12-12 AU AU2013359179A patent/AU2013359179B2/en not_active Ceased
- 2013-12-12 WO PCT/US2013/074786 patent/WO2014093690A1/en not_active Ceased
- 2013-12-12 EP EP17196662.5A patent/EP3326622B1/en active Active
- 2013-12-12 JP JP2015547567A patent/JP6345690B2/ja active Active
- 2013-12-12 ES ES17196662T patent/ES2862335T3/es active Active
- 2013-12-12 DK DK17196662.5T patent/DK3326622T3/da active
- 2013-12-12 EP EP13862780.7A patent/EP2931265B3/en active Active
- 2013-12-12 PT PT171966625T patent/PT3326622T/pt unknown
- 2013-12-12 PT PT138627807T patent/PT2931265T/pt unknown
- 2013-12-12 CA CA2894539A patent/CA2894539C/en active Active
- 2013-12-12 DK DK13862780.7T patent/DK2931265T6/da active
- 2013-12-12 ES ES13862780T patent/ES2665323T7/es active Active
-
2014
- 2014-06-30 NO NO14741534A patent/NO3049208T3/no unknown
-
2017
- 2017-10-13 US US15/783,850 patent/US11136563B2/en not_active Expired - Fee Related
- 2017-12-06 AU AU2017272193A patent/AU2017272193A1/en not_active Abandoned
-
2018
- 2018-05-23 JP JP2018098435A patent/JP6832887B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-02 AU AU2019210662A patent/AU2019210662B2/en not_active Ceased
-
2021
- 2021-09-02 US US17/465,203 patent/US20220220458A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2931265T3 (en) | 2018-04-16 |
| ES2665323T7 (es) | 2023-06-15 |
| EP3326622B1 (en) | 2021-01-20 |
| AU2013359179B2 (en) | 2017-10-05 |
| ES2862335T3 (es) | 2021-10-07 |
| AU2017272193A1 (en) | 2017-12-21 |
| AU2013359179A1 (en) | 2015-07-02 |
| WO2014093690A1 (en) | 2014-06-19 |
| US9822347B2 (en) | 2017-11-21 |
| DK2931265T6 (da) | 2023-05-01 |
| NO3049208T3 (enExample) | 2018-04-14 |
| CA2894539C (en) | 2021-09-28 |
| JP6832887B2 (ja) | 2021-02-24 |
| ES2665323T3 (es) | 2018-04-25 |
| CA2894539A1 (en) | 2014-06-19 |
| US20150315553A1 (en) | 2015-11-05 |
| US20180030422A1 (en) | 2018-02-01 |
| AU2019210662A1 (en) | 2019-08-22 |
| US11136563B2 (en) | 2021-10-05 |
| EP2931265A1 (en) | 2015-10-21 |
| HK1256071A1 (en) | 2019-09-13 |
| PT3326622T (pt) | 2021-04-07 |
| EP2931265A4 (en) | 2016-08-31 |
| JP2016510309A (ja) | 2016-04-07 |
| PT2931265T (pt) | 2018-04-16 |
| EP2931265B1 (en) | 2018-01-31 |
| US20220220458A1 (en) | 2022-07-14 |
| EP2931265B3 (en) | 2023-04-05 |
| EP3326622A1 (en) | 2018-05-30 |
| JP6345690B2 (ja) | 2018-06-20 |
| AU2019210662B2 (en) | 2021-07-01 |
| DK3326622T3 (da) | 2021-04-06 |
| JP2018154641A (ja) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2931265T6 (fi) | Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa | |
| JP2012082206A5 (enExample) | ||
| RU2011141522A (ru) | Антиангиогенные слитые белки | |
| IN2012DN03368A (enExample) | ||
| MX347200B (es) | Péptidos procoagulantes y sus derivados, y usos para estos. | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| JP2017160222A5 (enExample) | ||
| AR065289A1 (es) | Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple | |
| PH12014501083A1 (en) | Anticancer fusion protein | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2015524403A5 (enExample) | ||
| WO2016004906A3 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| JP2012529293A5 (enExample) | ||
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| JP5992529B2 (ja) | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 | |
| IL209595A (en) | Isolated nucleic acid, expression vector and host cell containing it, isolated polypeptide encoded by it and chimeric polypeptide containing it, process for preparation, oligopeptide hhipl l2 mimics loop, preparations containing it and methods for its production |